$0.24
-0.01 (-4.58%)
Open$0.24
Previous Close$0.25
Day High$0.24
Day Low$0.22
52W High$1.05
52W Low$0.23
Volume—
Avg Volume3.98M
Market Cap24.50M
P/E Ratio—
EPS$-0.31
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+6,478.9% upside
Current
$0.24
$0.24
Target
$15.75
$15.75
$10.91
$15.75 avg
$18.65
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 26.72M | 17.68M | 17.52M |
| Net Income | -25,885,885 | -69,679,191 | -1,532,650 |
| Profit Margin | -96.9% | -416.1% | -8.8% |
| EBITDA | -25,507,921 | -74,344,734 | -1,913,244 |
| Free Cash Flow | — | — | -1,533,941 |
| Rev Growth | +180.1% | -14.7% | +0.6% |
| Debt/Equity | 0.03 | 0.25 | 1.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |